Research programme: genomic therapeutics - Evotec AG/Toray
Latest Information Update: 10 Sep 2007
At a glance
- Originator Evotec AG; Toray
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 08 Sep 2007 Discontinued - Preclinical for Undefined indication in Japan (unspecified route)
- 08 Sep 2007 Discontinued - Preclinical for Undefined indication in Germany (unspecified route)
- 11 Feb 2004 Preclinical trials in Undefined indication in Japan (unspecified route)